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Pabry’s Disease Cardiomyopathy
chocardiographic Detection of
ndomyocardial Glycosphingolipid Compartmentalization
aurizio Pieroni, MD, PHD,* Cristina Chimenti, MD, PHD,†‡ Francesco De Cobelli, MD,§
manuela Morgante, MD, Alessandro Del Maschio, MD,§ Carlo Gaudio, MD,†
atteo Antonio Russo, MD,¶ Andrea Frustaci, MD†‡
ilan and Rome, Italy
OBJECTIVES We sought to identify echocardiographic hallmarks of Fabry’s disease cardiomyopathy (FC).
BACKGROUND The recognition of FC from other forms of left ventricular hypertrophy (LVH) by
noninvasive imaging techniques is not yet available, and diagnosis, mostly in the absence of
systemic manifestations, still relies on genetic and invasive studies.
METHODS Forty consecutive patients (mean age 39  15 years, 22 men and 18 women) with an
established diagnosis of Fabry’s disease were submitted to echocardiographic evaluation.
Control population consisted of 40 consecutive patients with hypertrophic cardiomyopathy
(HCM), 40 hypertensive patients with echocardiographic evidence of LVH, and 40 age- and
gender-matched healthy subjects with no LVH. All HCM patients and FC with LVH and/or
cardiac symptoms underwent cardiac catheterization with left ventricular endomyocardial biopsy.
RESULTS Echocardiography showed in 83% of FC patients (95% of FC patients with LVH) a binary
appearance of endocardial border absent in all HCM, hypertensive, and healthy subjects. The
sensitivity and specificity of this echocardiographic feature in detecting Fabry patients in study
population were 94% and 100%, respectively. Comparison of echocardiographic with
histologic and ultrastructural findings showed the binary appearance to reflect an endomyo-
cardial glycosphingolipids compartmentalization, consisting of thickened glycolipid-rich
endocardium, free glycosphingolipid subendocardial storage, and an inner severely affected
myocardial layer with a clear subendocardial-midwall layer gradient of disease severity.
CONCLUSIONS Echocardiographic binary appearance of left ventricular endocardial border, reflecting
endomyocardial glycosphingolipids compartmentalization, represents a sensitive and specific
diagnostic hallmark of Fabry’s disease cardiomyopathy. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.0701663–71) © 2006 by the American College of Cardiology Foundation
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2abry’s disease is an X-linked disorder caused by deficiency
f lysosomal enzyme alpha-galactosidase A, resulting in
rogressive intracellular accumulation of glycosphingolipids
n different tissues, including skin, kidneys, vascular endo-
helium, ganglion cells of peripheral nervous system, and
eart (1). Cardiac involvement is characterized by progres-
ive left ventricular hypertrophy (LVH) that mimics the
orphologic and clinical features of hypertrophic cardiomy-
pathy (HCM) (2,3). Indeed, Fabry’s disease cardiomyop-
thy (FC) has been reported in up to 6% of men (3) and
2% of women (4) with late-onset HCM. In particular, the
eart can be the only organ involved in male patients with
pecific gene mutations (2) and in female carriers where the
early normal enzymatic activity and the lack of systemic
anifestations make its identification more difficult (5).
he recognition of Fabry’s disease has recently become
ore relevant as enzyme replacement (6) and enzyme
nhancement (7) therapy have proved effective in reducing
From the *Ospedale Multimedica, Milan, Italy; †Heart and Great Vessels
epartment “Attilio Reale,” “La Sapienza” University, Rome, Italy; ‡National
nstitute for Infectious Diseases “Lazzaro Spallanzani,” Rome, Italy; §Radiology
epartment, San Raffaele Hospital, Milan, Italy; Pathology Department, “La
apienza” University, Rome, Italy; and ¶“San Raffaele Pisana” Institute, Rome, Italy.
his study was supported by Telethon Foundation grant GGP05264 (Rome, Italy)
nd partially supported by a grant from Genzyme Europe.y
Manuscript received October 4, 2005; revised manuscript received November 1,
005, accepted November 22, 2005.lycosphyngolipids accumulation and in clearing existing
eposits with improvement of cardiac function.
To identify undiagnosed patients affected by FC, assess-
ent of alpha-galactosidase A activity in peripheral blood
ymphocytes in all patients with unexplained LVH has been
roposed. However, this approach, considering the low
revalence of Fabry’s disease in the general population (1),
mplies relevant costs and therefore may be limited to
ertiary referral centers. In addition, measurement of alpha-
alactosidase A activity in peripheral blood may be unreli-
ble in female carriers, who frequently show clinical mani-
estations of the disease in the presence of normal enzymatic
ctivity (4,8). Moreover, even recently developed imaging
echniques (9–12) appear ineffective in distinguishing FC
rom HCM and thereby focusing the enzymatic activity
creening in patients with unexplained LVH.
In the present study, we compared echocardiographic
eatures of patients with FC, HCM, and LVH secondary to
ypertension in order to identify non-invasive imaging
allmarks in patients with an established diagnosis of FC.
ETHODS
atient population. From January 1996 to December
004, we studied 40 consecutive patients (mean age 39 15
ears, 22 men and 18 women) from 12 different families
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Echocardiographic Hallmark of Fabry Cardiomyopathy April 18, 2006:1663–71ho received a diagnosis of Fabry’s disease on the basis of
educed alpha-galactosidase A activity in peripheral blood
ymphocytes and/or genetic analysis. Among these, 20 patients
group A) presented LVH with a maximal wall thickness15
m at echocardiographic evaluation, whereas 20 subjects
group B) showed mild (maximal wall thickness 15 mm)
n  13) or no (n  7) LVH. The control population
onsisted of 40 consecutive patients with HCM, 40 hyper-
ensive patients with echocardiographic evidence of LVH,
nd 40 age- and gender-matched healthy subjects with no
VH.
As our institution is a tertiary referral center dedicated to
he study of heart muscle diseases, all HCM patients, all
roup A Fabry patients, and group B patients presenting
ardiac symptoms were submitted to cardiac catheterization
ith endomyocardial biopsy to assess the severity of cardiac
nvolvement. In addition, all patients with FC and 30
atients with HCM also underwent cardiac magnetic reso-
ance (CMR) with late gadolinium enhancement study as
art of the diagnostic process.
iochemical studies. Alpha-galactosidase A activity was as-
essed in white blood cells in all patients. Lymphocytes were
solated by gradient centrifugation (Lymphoprep, Nycomed,
slo, Norway), washed in phosphate-buffered saline, and
omogenized in distilled water. The resulting lymphocyte
upernatant was assayed with 4-methylumbelliferyl-alpha-
-galactoside for alpha-galactosidase A activity (measured
s nanomoles per hour per milligram of protein) (7).
ormal values were considered between 1,619 and 3,044
mol/h/1 mg protein.
enetic analysis. Genomic deoxyribonucleic acid was iso-
ated from peripheral blood (Puregene DNA isolation kit,
entra Systems, Minneapolis, Minnesota), and all of the
lpha-galactosidase A coding regions and adjacent intronic
egions were sequenced as previously described (7).
chocardiographic studies. All echocardiographic studies
ere performed with Agilent Sonos 5500 (Hewlett-
ackard, Palo Alto, California), Toshiba Powervision 6000
Toshiba America Medical Systems, New York, New
ork), and Aplio 80 ultrasound systems (Toshiba America
edical Systems). Patients were imaged, and data were
nalyzed offline by two experienced investigators unaware of
he underlying cardiomyopathy and blind to clinical data. In
ase of difference in terms of measurement or functional and
orphologic assessment, a consensus value was reached in
ll cases with the help of a third experienced echocardiog-
apher. Left ventricular septal, posterior, and maximal wall
Abbreviations and Acronyms
CMR  cardiac magnetic resonance
FC  Fabry’s disease cardiomyopathy
HCM  hypertrophic cardiomyopathy
LV  left ventricle/ventricular
LVH  left ventricular hypertrophyhicknesses; end-diastolic and end-systolic dimensions; ajection fraction; fractional shortening; and left atrial vol-
mes were determined according to established criteria (13).
aximal wall thickness was defined as the greatest thickness
easured at any segment of left ventricular (LV) wall. A LV
utflow gradient 30 mm Hg at rest was considered
ignificant. Peak early (E) and late (A) transmitral filling
elocities, E/A ratio, deceleration time of E velocity, and
sovolumic relaxation time were measured from mitral
nflow velocities (9). In all patients, tissue Doppler studies
ere also performed as previously described (9).
MR studies. Cardiac magnetic resonance was performed
n a 1.5-T whole-body scanner (Gyroscan Intera Master
.5 MR System, release 9.0, Philips Medical Systems, Best,
he Netherlands) by using an enhanced gradient system with
maximum gradient strength of 30 mT/m and a maximum
radient slew rate of 150 mT/m1·s1 and a five-element
ardiac phased-array coil (SENSE-cardiac). Black blood
orphologic images in the cardiac short-axis, four chamber
ong-axis, and two chamber long-axis planes were acquired
y using T2-weighted sequences without and with fat
uppression. In the same planes, cine-magnetic resonance
maging was performed by using a breath-hold balanced fast
eld-echo sequence. The cine-magnetic resonance short-
xis images encompassed the entire left ventricle from the
ase to the apex (stack of 8 to 12 contiguous short-axis
lices; thickness  8 mm, gap  2 mm) in order to obtain
volumetric evaluation in a three-dimensional fashion. Late
nhancement assessment was performed 10 to 15 min after
njection of gadolinium-DTPA (Shering AG) (0.2 mmol/
g of body weight), by using a three-dimensional inversion
ecovery T1-weighted sequence. Two consecutive stacks, each
omposed of 10 contiguous slices (20 slices; thickness 5 mm,
ap  0 mm) were acquired in the short-axis plane to
ncompass the entire left ventricle. Total acquisition time
as about 40 min.
MR imaging analysis. Image analysis was performed
sing an image-processing workstation (EasyVision, Philips
edical Systems) with the cardiac analysis software package
release 5x). End-diastolic volume, end-systolic volume,
troke volume, and ejection fraction of the LV were calcu-
ated. Left ventricle myocardial mass was automatically
btained by multiplying the wall volume with the specific
yocardial weight (1.05 g/cm3). The volume of hyperen-
anced tissue was calculated on short-axis images and the
ercentage of late enhancement was given by the ratio
etween volume of hyperenhanced tissue and volume of LV
yocardium 100.
The cine and contrast-enhanced images were evaluated
eparately by the consensus of two expert observers, who
ssessed the location of any hyperenhanced regions; the
nhancement patterns were described as focal, diffuse, or in
triae, and wall location was described as subendocardial,
esocardial (midwall), subepicardial, or transmural.
ardiac catheterization and endomyocardial biopsy. All
nvasive studies conformed to the Declaration of Helsinki
nd were performed after patient written informed consent
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April 18, 2006:1663–71 Echocardiographic Hallmark of Fabry Cardiomyopathynd approval by the ethical committee of our institution. All
atients submitted to cardiac catheterization underwent
oronary and LV angiography with LV endomyocardial
iopsy. Endomyocardial biopsies were performed in the
eptal-apical region of the LV. At least six endomyocardial
amples were obtained from each patient and were pro-
essed for histology, immunohistochemistry, and transmis-
ion electron microscopy (9).
istology, immunohistochemistry, and electron micros-
opy. Histology and electron microscopy studies were per-
ormed by a pathologist blind to imaging and molecular and
enetic studies. Three to four specimens were fixed in 10%
uffered formalin and embedded in paraffin wax; 5-m cut
ections were stained with hematoxylin and eosin, Miller’s
lastic van Gieson, and Masson’s thrichrome. One to two
amples were immediately frozen in optimal cutting tem-
erature compound with isopentane cooled in liquid nitro-
en and stained with periodic acid-Schiff and Sudan black
n order to assess the presence of glycolipids storage as
reviously described (4,7). Two myocardial samples were
xed in 2% glutaraldehyde in 0.1-m phosphate buffer (pH
7.3) and embedded in Epon resin; semithin sections were
rocessed for Azur II staining while ultrathin sections were
tained with uranyl acetate and lead hydroxide (4,7,9) for
lectron microscopy analysis.
Measurements on myocardial tissue sections were per-
ormed using a semi-automated system (Lucia G software
ersion 4.82, Nikon, Japan). The degree of myocyte hyper-
rophy was assessed by means of cellular diameter at nuclear
evel in transverse sections. Endocardial thickness was mea-
ured in all patients. In addition, in Fabry patients in-
ramyocyte vacuoles as percent of total cell area were
easured in 20 random high-power fields (400) in sub-
ndocardial and inner myocardial cells in each specimen,
nd a mean value was calculated for each patient.
tatistical analysis. Normal distribution of explored vari-
bles was assessed with Shapiro-Wilk test. Continuous
ariables are presented as mean  SD. Categorical variables
re presented as proportions or percentages. Comparisons of
able 1. Causal Mutations in the Alpha-Gal Gene Identified in
Family
Exon/Intron
Location
Nucleotide
Change
E
I Exon 6 C946 delG Fra
II Exon 2 c334 CT Am
III Exon 7 c1133GA Am
IV Intron3 IVS3  1GA Spl
V Exon 1 c119 CT Am
VI Exon 6 c982 GA Am
VII Exon 7 del CT Fra
VIII Exon 5 c680AT Am
IX Exon 1 c126-127 insCATG Fra
X Exon 5 c215 AG Am
XI Exon 6 c835 CA Am
XII Exon 5 c220 CT Am
el  deletion; ins  insertion; IVS  intervening sequence.roportions between groups were performed with chi- mquare test; in the case of 2  2 tables with an expected cell
ount of 5, Fisher exact test was used. Between-groups
omparisons of variables showing normal distribution and
omogeneous variance (as assessed by Levene’s test) were
erformed with one-way ANOVA; in the case of between-
roups significant differences at one-way ANOVA, a post-hoc
nalysis was performed with Scheffé test. Between-groups
omparisons of variables not showing normal distribution were
erformed with Kruskal-Wallis test; in the case of overall
etween-groups significant differences at Kruskal-Wallis
est, direct comparisons were performed with Mann-
hitney test. The significance level was set at p  0.05. In
he case of multiple comparisons, the alpha level of Mann-
hitney test was divided by the number of multiple
omparisons performed.
ESULTS
ausal mutations identified in the 12 families are reported
n Table 1. Each group included both male and female
atients from at least nine families. Group B patients were
ounger than group A (28  9 years vs. 51  12 years, p 
.01) and included a similar number of women (10 vs. 8 in
roup A). Clinical characteristics, signs, and symptoms of
ardiac involvement and extra-cardiac manifestations are
eported in Tables 2 and 3. Alpha-galactosidase A activity
as very low (mean value 65.6  75.3, range 9.2 to 360.43
mol/h/mg of protein) in all male patients. Heterozygote
emales showed from intermediate to very low values of
lpha-Gal A activity (mean value 797.9  233.2, range
34.1 to 1,082.15 nmol/h/mg of protein), and clinical
anifestations ranged from absence of signs and symptoms
f the disease to severe systemic involvement. Complex and
epetitive ventricular extrasystoles (Lown class III to IVa)
ere present at Holter monitoring in 10 group A patients
nd in 11 group B patients. Extra-cardiac manifestations
ere present in 16 group A Fabry patients and in 17 group
patients. In female patients clinical manifestations and in
articular cardiac involvement were more common and
2 Fabry Families Studied
on Coding
quence Genotype Reference
ift/stop codon c946 del G Morrone 2002
cid change R112C Ishii 1992
cid change C378Y Topaloglu 1999
defect IVS3  1GA Aston-Prolla 2000
cid change P40L Aston-Prolla 2000
cid change G328R Ishii 1992
ift/stop codon L344-X28-Stop Germain 1996
cid change R227Q Eng 1993
ift/stop codon c126-127 insCATG Morrone 2002
cid change N215S Eng 1993
cid change Q279K Dominissini 2004
cid change R220X Meaney 1994the 1
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Echocardiographic Hallmark of Fabry Cardiomyopathy April 18, 2006:1663–71rs, cardiac involvement represented the only manifestation
f the disease, whereas in two other female patients ocular
nvolvement was the only accompanying manifestation.
At the time of the present study, all patients were
eceiving enzyme-replacement therapy according to drugs
nd dosages currently approved in Europe (either agalsidase
able 2. Genetic, Clinical and Echocardiographic Features of Pa
Patient Age/Gender Family
Enzymatic Activity*
(nmol/h/mg of Protein)
1 46/M I 20.90  1.46 Dys
2 55/F I 589.10  46.25 Dys
3 46/M II 30.56  6.33 Dys
4 33/M III 103.08  13.51 VA
5 39/M IV 360.43  16.34 Dys
6 35/M V 9.2  0.19 Dys
7 43/M VI 136.00  21.1 Dys
8 49/F VII 1,027.10  56.47 Dys
9 52/F VIII 923.15  73.00 Dys
10 48/M IX 70.26  9.55 Dys
11 60/F X 378.48  14.56 Dys
12 70/F X 831.62  49.36 Dys
13 40/M X 75.60  19.42 Dys
14 69/M X 50.23  5.62 Dys
15 66/F XI 964.00  21.52 Dys
16 63/M XI 36.10  1.90 Dys
17 61/F XI 722.47  39.11 Dys
18 59/F XI 799.42  37.00 Dys
19 35/M XI 15.23  0.78 Dys
20 41/M XII 23.11  2.62 Dys
Values are the mean ( SD) results of three independent determinations on periph
AP  acroparesthesias; CNS  central nervous system; H  hypoidrosis; VA 
able 3. Genetic, Enzymatic and Clinical Characteristics of Patie
Patient Age/Gender Family
Enzymatic Activity*
(nmol/h/mg of Protein) Card
1 17/F I 134.12  21.68
2 23/M I 28.29  6.52 VA
3 26/M I 17.05  3.68 VA
4 14/F I 722.10  35.12
5 36/F II 905.15  52.11 VA
6 42/F II 1030.15  78.05 VA
7 18/M III 21.30  3.79 VA,
8 19/M III 27.59  4.10 VA,
9 19/F VII 1082.15  58.65
10 22/M VII 23.79  4.14
11 27/M VIII 99.00  19.09 VA
12 30/M VIII 70.00  1.95 VA
13 29/M IX 123.04  40.27
14 30/M IX 44.20  7.87
15 32/F X 964.12  42.45
16 33/F XI 905.24  33.10
17 32/M XI 59.33  2.78 Dysp
18 34/F XI 882.29  19.65 Dysp
19 40/F XII 654.55  32.26 Dysp
20 44/F XII 748.45  29.64 DyspValues are the mean ( SD) results of three independent determinations on peripheral b
Abbreviations as in Table 2.eta 1 mg/kg of body weight or agalsidase alpha 0.2 mg/kg
f body weight) from at least three months (mean 10  6
onths, range 3 to 16 months).
chocardiographic studies. Main echocardiographic find-
ngs are reported in Table 4. Differences between observers
ccurred in 7% of cases and were always 1.5 mm. In
With Fabry Disease and MWT 15 mm
ardiac
ifestations
Extracardiac
Manifestations
MWT
(mm)
Binary
Endocardial
Border
chest pain, VA Skin, eyes, ears, kidneys,
CNS, AP, H
21 Yes
Eyes, ears, AP, H 20 Yes
VA Skin, eyes, ears, kidneys,
CNS, AP, H
19.5 Yes
AP, skin, eyes 18.5 Yes
AP, skin, eyes 17 Yes
AP, skin, eyes 18.5 Yes
chest pain, VA — 20 Yes
— 17 Yes
VA — 16.5 Yes
VA Skin, eyes, H 16 Yes
Eyes, ears, kidneys 20 Yes
chest pain, VA Eyes, ears 15.5 Yes
Skin, eyes, ears, kidneys,
CNS
15.5 Yes
chest pain, VA Eyes, ears, kidneys 19 Yes
VA Eyes, ears, kidneys 16.5 Yes
chest pain, VA Eyes 18 Yes
VA Eyes 17.5 Yes
— 18 Yes
chest pain, VA Skin, eyes, ears, kidneys,
CNS
16.5 Yes
chest pain, VA Skin, eyes, ears, kidneys 17.5 Yes
lood lymphocytes.
icular arrhythmias (Lown class III to IVa).
ith Fabry Disease and MWT 15 mm
anifestations
Extracardiac
Manifestations
MWT
(mm)
Binary Endocardial
Border
— AP, eyes, ears 10 No
AP, eyes, ears 13 Yes
AP, eyes, ears, skin 13 Yes
— 10 No
— 12.5 Yes
— 13 Yes
ea, chest pain — 12.5 No
ea, chest pain — 13.5 Yes
— AP, H 10 No
— AP, skin, ears, eyes 14 Yes
AP 12.5 Yes
AP 14 Yes
— AP, skin, ears, eyes 13 Yes
— AP, skin, ears, eyes 13.5 Yes
— — 10.5 No
— Eyes 11 No
Eyes, ears 13 Yes
A Eyes, ears 13 Yes
A Eyes, ears, kidneys 12.5 No
A Eyes, ears, kidneys 14.5 Yestients
C
Man
pnea,
pnea
pnea,
pnea
pnea
pnea,
pnea
pnea,
pnea,
pnea
pnea,
pnea
pnea,
pnea,
pnea,
pnea,
pnea
pnea,
pnea,nts W
iac M
dyspn
dyspn
nea
nea, V
nea, V
nea, Vlood lymphocytes.
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April 18, 2006:1663–71 Echocardiographic Hallmark of Fabry Cardiomyopathyroup B Fabry patients, LVH (maximal wall thickness 11
m) was observed in 15 cases. Patients with HCM showed
igher maximal wall thickness and lower LV end-diastolic
iameter in comparison with both FC and hypertensive
atients and more frequently presented asymmetric hyper-
rophy and outflow tract gradient. No differences in terms of
entricular and atrial dimensions, systolic function, or presence
nd degree of mitral regurgitation were observed between
CM and group A patients. Diastolic function was sys-
ematically impaired with a similar prevalence of restrictive
lling pattern in HCM and group A patients.
able 4. Echocardiographic Data of Study Population
FC Group A
(n  20)
FC Group
(n  20
ge, yrs 51  12* 28  9*
en/women, n 12/8 10/10
aximal wall thickness, mm 17.9  1.6* 12.5  1.4
V outflow tract gradient 0 0
V end-diastolic diameter, mm 45.8  2.2 47.7  3.2
V ejection fraction, % 60  5 64  4
ractional shortening, % 41  4 42  4
/A ratio 1.0  0.3† 1.2  0.4
sovolumic relaxation time, ms 108.7  11.6§ 76.6  7.8
-wave deceleration time, ms 220.8  31.4 177.3  22
estrictive filling pattern 0 0
itral regurgitation 6 (30)† 5 (25)†
ndocardial binary appearance 20 (100)¶ 13 (65)¶
ata are presented as the mean value  SD or n (%) of patients. *p  0.01 vs. all ot
ontrols; §p  0.01 vs. FC Group B, hypertensive patients and controls; p  0.01
nalysis of variance was applied in the comparison of ejection fraction, Kruskal-Walli
ategorical variables.
FC  Fabry cardiomyopathy; HCM  hypertrophic cardiomyopathy; LV  left
igure 1. Two-dimensional echocardiography in four-chamber apical view
atient #18 of Table 2) with Fabry’s disease cardiomyopathy (A,D and
omparison of the three echocardiographic frames reveals the presence of a
A,B). This echocardiographic finding reflects the glycosphingolipids com
ngulfed smooth muscle cells (SMC), a subendocardial empty space (SES
he middle layer (ML) appears partially spared (D,E). The echocardiographic
hickening of the endocardium (F).Among subjects with FC, all group A patients and 13
roup B patients showed a binary appearance of LV
ndocardial border, more evident in the left side of
nterventricular septum but observable in most cases all
long the LV chamber contour and, in some patients with
arked LVH and an optimal acoustic window, even in
he right side of interventricular septum and free right
entricular wall (Fig. 1A). Interestingly, binary endocar-
ial appearance also was observed in three group B
atients (Patients #10, #13, and #14 in Table 2) present-
ng mild LVH but no symptoms of cardiac involvement
HCM
(n  40)
Hypertensive Patients
(n  40)
Controls
(n  40)
40  6 40  8 41  6
22/18 20/20 20/20
27.0  5.0* 12.7  2.6† 8.7  1.0
10 (25%) 0 0
39.1  3.5* 49.0  3.4 47.0  1.8
67  5‡ 57  7 60  3
40  7 42  6 39  6
1.0  0.7† 1.2  0.3 1.4  0.2
109.2  17.8§ 87.4  3.4† 78.9  8.7
210.2  37.7 235.7  36.7 185.8  31.4
5 (25) 0 0
14 (35)† 12 (30)† 0
0 0 0
oups; †p  0.01 vs. controls; ‡p  0.01 vs. FC Group A, hypertensive patients and
Group B and controls; ¶p  0.01 vs. HCM, hypertensive patients, and controls.
ll other continuous variables. Chi-square test was applied in all comparisons between
icular.
left ventricular endomyocardial biopsy from two patients (Patient #4 and
, respectively) and a patient with hypertrophic cardiomyopathy (C,F).
appearance of left ventricular endocardial border in the two Fabry patients
entalization involving a thickened endocardium (End) with enlarged and
a prominent involvement of subendocardial myocardial layer (SL), whileB
)
†
.4†
her gr
vs. FC
s for aand
B,E
binary
partm
), andpattern is absent in hypertrophic cardiomyopathy (C), despite a similar
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Echocardiographic Hallmark of Fabry Cardiomyopathy April 18, 2006:1663–71Fig. 1B). In the Fabry patient population studied, the
revalence of the echocardiographic feature was 82.5%,
eaching 94% when considering only patients with LVH.
hese findings were reported by all echocardiographers
ho analyzed images and were considered independent
rom the ultrasound system used, from gain settings, and
ostly from the application of tissue harmonic imaging
oftware. Remarkably, this binary appearance of endocar-
ial border was not observed in any of the HCM (Fig.
C) and hypertensive patients or in healthy control
ubjects included in the study. In these settings, the
ensitivity and specificity of echocardiographic binary
ppearance in our population of patients with mild to
evere LVH were 94% and 100%, respectively, with a
ositive predictive value of 100% and a negative predic-
ive value of 94%.
Tissue Doppler analysis showed a significant reduction of
oth diastolic and systolic velocities in all three groups
ompared with control patients (Table 5). Remarkably, no
ignificant difference was observed between group A pa-
ients and HCM patients in terms of myocardial velocities.
nterestingly, group B patients were mostly undistinguish-
ble from hypertensive subjects on the basis of echocardio-
raphic and tissue Doppler findings, as only systolic velocity
t lateral corner was significantly different in the two groups.
MR imaging analysis. Cardiac magnetic resonance con-
rmed the LV morphologic and functional data observed at
chocardiography in all patients. No specific signal in the
ndocardial and subendocardial layers distinguishing FC from
CM was observed. Gadolinium contrast-enhancement
tudies showed the presence of late enhancement in 20
atients (50%) with HCM and in 10 group A patients
50%) with FC.
In HCM, contrast enhancement showed a focal pattern
n 15 cases and a diffuse pattern in 5 cases. Focal late
nhancement areas were mostly localized in the interven-
ricular septum and papillary muscles, but in nine patients
ith concentric hypertrophy, the areas were also localized in
he basal segments of lateral and inferior wall. In patients
ith FC, late enhancement was localized in all cases in the
able 5. Tissue Doppler Data of Study Population
FC Group A
(n  20)
FC Group B
(n  20)
eptal Sa, cm/s 6.4  0.8* 8.3  0.8†
eptal Ea, cm/s 6.0  0.9* 8.5  0.6‡
eptal Aa, cm/s 6.8  1.0* 8.9  0.3†
eptal Ea/Aa, cm/s 0.97  0.2‡ 0.98  0.34†
eptal E/Ea, cm/s 13.6  2.0* 9.78  1.32§
ateral Sa, cm/s 6.5  0.8* 8.6  0.8‡
ateral Ea, cm/s 6.2  1.0* 8.9  0.5†
ateral Aa, cm/s 7.4  1.4* 9.1  0.7†
ateral Ea/Aa, cm/s 0.96  0.17† 0.99  0.11†
ateral E/Ea, cm/s 11.95  3.0* 9.3  1.15‡
p  0.01 vs. FC Group B, hypertensive patients and controls; †p  0.01 vs. contr
ruskal-Wallis test.
Abbreviations as in Table 4.asal or basal-medium segments of lateral and infero-lateral talls as previously reported (10). In one patient with more
evere LV hypertrophy (Patient #1 of Table 2), a focal
idwall late-enhancement area was also observed at the
pex. The mean percentage of myocardium involved by late
adolinium enhancement in FC patients was 7.8  7.4%
range 0 to 19%).
ardiac catheterization. All HCM patients and 35 Fabry
atients, including all group A patients and 15 group B
atients, were submitted to cardiac catheterization and
ndomyocardial biopsy. In the remaining five group B
atients, all of them female carriers, cardiac catheterization
as not performed, as the patients did not present LVH or
ardiac symptoms. In all cases, coronary angiography was
ormal and all HCM and FC patients showed increased LV
nd-diastolic pressure with higher values in HCM (23.2 
.3 mm Hg) and group A patients (21.1  6.4 mm Hg)
ompared with group B patients (15.6  5.8 mm Hg, p 
.01).
istology, immunohistochemistry, and electron micros-
opy. In all patients with Fabry’s disease, histology showed
t hematoxylin and eosin staining a diffuse vacuolization of
yocytes, endothelial cells, and smooth muscle cells; these
acuoles were positive at Sudan-Black staining and con-
isted at electron microscopy of concentric lamellar figures
n single-membrane bound vesicles (myelin bodies), denot-
ng glycosphingolipids accumulation. A gradient in myocar-
ial disease severity was observed in all patients; the suben-
ocardial layers were more severely affected in comparison
ith outer myocardial layers: subendocardial myocytes were
igger (diameter at nuclear level 60  12 m vs. 28  13
m in group A, 44  9 m vs. 19  7, p  0.001 in group
) and characterized by larger intracellular glycolipid vacu-
les than midwall layer myocytes (79  12% vs. 31  9% of
ell area in group A; 45  15% vs. 22  6% in group B, p
0.001) (Figs. 1D and 1E). As previously described (4),
emale carriers presented a patchy distribution of affected
reas in the outer myocardial layers but a similar gradient of
isease severity.
The endocardium was severely thickened (88  12
m, range 73 to 100 m in group A; 64  13, range 42
HCM
(n  40)
Hypertensive Patients
(n  40)
Controls
(n  40)
5.9  0.6* 9.3  1.7† 14.12  1.78
5.6  1.1* 8.7  2.0† 15.01  2.05
6.4  1.4* 9.3  1.9† 10.5  1.9
0.96  0.21‡ 0.99  0.19† 1.7  0.4
13.9  1.1* 9.6  1.4† 6.1  1.0
6.2  1.0* 10.1  1.3† 13.2  1.5
5.8  0.7* 9.6  2.2† 13.1  2.1
7.1  1.3* 10.1  1.7 10.1  1.6
0.91  0.23‡ 1.04  0.24† 1.4  0.4
12.9  2.1* 8.65  2.3† 5.5  1.5
 0.01 vs. hypertensive patients and controls. All comparisons were performed byols; ‡po 79 m in group B) mostly due to glycolipid-engulfed
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olipids. In addition, an empty space between endocar-
ium and myocardium observed at histology (Fig. 2A)
ppeared to be represented at electron microscopy by free
lycosphingolipids organized in myelin bodies (Fig. 2B).
he extracellular glycosphingolipids observed in endocar-
ium and subendocardial space were found to derive from
eath of severely affected cells as well as from glycolipid
ecretion by massively engulfed cells, as shown at electron
icroscopy (Fig. 2C). The combination of endocardium,
igure 2. Semithin (A) and ultrathin (B,C) sections from left ventricular
smiophilic bodies intensely stained by Azur II are seen in the endocardium
hey are localized in the region of empty spaces seen at H and E histology se
rom the subendocardial to the inner layer. At electron microscopy (B,C
embrane-bounded bodies diffusely present in the context of the endocar
nside the myocytes (Myo). Arrows indicate membrane-bounded bodie
uggesting a process of release from the cell to the extracellular space. (A)ubendocardial empty space, and severely affected myocar- iium constituted a glycolipid-rich inner layer in all patients,
ith a mean thickness of 640  118 m, (range 500 to 800
m) in group A patients and 440  98 m (range 290 to
40 m) in group B.
In HCM patients, histology showed in all cases the
resence of severely hypertrophied myocardiocytes, often in
otal disarray and frequently interrupted in short runs
ecause of interstitial and various degrees of replacement
brosis. In these patients, the endocardium was significantly
hickened (86  32 m, range 50 to 110 m) owing to an
yocardial biopsy of the same patient of Figures 1A and 1D. In panel A,
he subendocardial space, and in myocardium. In the subendocardial space,
. In the myocardial tissue, a gradient of storage material can be appreciated
osmiophilic bodies appear to consist of glycosphingolipids organized in
(End), occupying the subendocardial space as a free storage material and
he boundaries between a myocardiocyte and the subendocardial space,
r II original magnification 100. (B,C) Bars  1 m.endom
, in t
ctions
) the
dium
s at tncrease of fibrous tissue (Fig. 1F). At electron microscopy,
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isorganization.
orrelation between imaging and pathology findings in
abry patients. With regard to the process of image
ormation, at ultrasound evaluation fat/muscle interface is
haracterized by both a significant refraction, with about 19
egrees of deviation (14), and reflection, with percent of
nergy reflected higher than muscle/blood interface (15). In
ddition, the glycosphingolipid nature of intracellular stor-
ge material organized in concentric lamellar bodies further
ncreases the acoustic impedance of affected tissues (16),
eading the digital image processing to depict an echodense
nd thick endocardial border paralleled by shadowing of the
idwall portion of ventricular walls. Concerning the spatial
esolution of ultrasound technique, as well as the shrinking
f myocardial samples produced by fixation, inclusion, and
taining procedures, the previously mentioned inner
lycolipid-rich layer may reasonably account for the images
bserved at two-dimensional echocardiography.
ISCUSSION
on-invasive identification of cardiomyopathies character-
zed by LV wall thickening is often difficult, and differential
iagnosis frequently relies on invasive studies such as endo-
yocardial biopsy or molecular and gene analysis. In par-
icular, FC shares several clinical and morphologic features
ith HCM (4–8), including electrocardiographic and echo-
ardiographic signs of LVH, reduced diastolic and systolic
issue Doppler velocities (9,11), and late-enhancement myo-
ardial areas at cardiac magnetic resonance (10,12). In these
ettings, in the absence of systemic manifestations of the
isease, as observed in the cardiac variant (3,8) and fre-
uently in female carriers (6,7), FC may appear undistin-
uishable from HCM and other forms of unexplained
VH, as demonstrated by recent studies reporting a signif-
cant prevalence of previously unrecognized FC in male and
emale patients with an established diagnosis of HCM (3,4).
evertheless, the recent development of specific therapeutic
trategies (6,7) may change the natural history and progno-
is of FC, making more relevant a proper and early diag-
osis.
In the present study, we identified a specific echocardio-
raphic feature of FC reflecting the peculiar pathological
ubstrate of the disease observed at histology and ultrastruc-
ural analysis of endomyocardial biopsy tissue. Ultrasound
xamination in Fabry patients revealed a binary appearance
f LV endocardial border, systematically absent in HCM
nd hypertensive patients as well as in normal control
atients, thereby resulting in a distinguished echocardio-
raphic feature with a sensitivity and specificity of 94% and
00%, respectively. The pathological substrate underlying
chocardiographic findings was represented by an endocar-
ial and subendocardial glycosphingolipid compartmental-
zation consisting of close succession of a thickened endo-
ardium, rich in glycolipid-engulfed endothelial and smooth nuscle cells, a free glycosphingolipids subendocardial layer,
n inner portion of severely affected myocardium, and outer
ildly to moderately affected myocardial tissue. This
ndocardial-epicardial gradient of disease severity observed in
ur Fabry patients is common in storage and infiltrative
ardiomyopathies and has been recently reported in a study
omparing CMR and pathology findings in cardiac amy-
oidosis (17). The possible mechanism underlying this
eature may be represented by the remarkable increase of LV
nd-diastolic pressure, leading to hypoperfusion and prom-
nent damage of subendocardial layers preceding the devel-
pment of relevant LVH (9).
Concerning the process of image formation, and when
onsidering the spatial resolution limits of the imaging
echniques, this complex pathological substrate can be
egarded as an inner glycolipid-rich layer including endo-
ardium, free glycosphingolipids, and severely affected myo-
ardium, and an outer layer represented by a mildly affected
yocardium corresponding to the midwall portion of ven-
ricular wall. In these settings, ultrasounds depict a thick
yper-echogenic layer representing the inner glycolipid-rich
ayer, paralleled all along the ventricular contour by an
ypo-echogenic layer reflecting the mildly affected midwall
yocardium, or possibly a shadowing artifact explained by
he high reflection and refraction index of the intracellular
ipids-rich layers. On this basis, whether a realistic repro-
uction of the pathological substrate or a combination of
rue images with artifacts, the identification of a disease-
pecific glycosphingolipids subendocardial compartmental-
zation strongly supports the reliability of binary endocardial
ppearance as a non-invasive hallmark of FC. Interestingly,
MR gadolinium-enhancement studies failed to identify
ny endocardial abnormalities in our Fabry patients,
hereas myocardial areas of late enhancement in the
ostero-basal segment previously described as typical of FC
10) were present in 10 out of 20 Group A patients. These
ndings are not surprising, as late gadolinium-enhancement
ostly reflects interstitial expansion even in endocardial
nd subendocardial portions of ventricular wall, as recently
eported by Maceira et al. in cardiac amyloidosis (17) and
herefore could not identify the prevalent intracellular
lycolipid accumulation occurring in subendocardial layers
f FC.
linical implications. The echocardiographic detection of
ndomyocardial compartmentalization was observed in 94%
f patients with FC and LVH and was not detectable in five
atients with no LVH and in two patients with initial LV
all thickening. These findings confirm that binary endo-
ardial pattern reflects the progressive deposition of glyco-
phingolipids and, therefore, the severity of the cardiac
nvolvement. The presence of binary aspect of the endocar-
ium even in younger patients with mild LVH strengthens
ts diagnostic value, supporting its clinical utility in extensive
creening and probably in monitoring treatment efficacy.
With this regard, it must be emphasized that the diag-
osis of Fabry disease relies mostly on clinical evaluation,
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s the evaluation of family members; nevertheless, these
ssues may result unattended in the absence of remarkable
xtra-cardiac signs, as frequently occurring in the cardiac
ariant of the disease and mostly in female carriers. In
linical practice, given that the heart and the kidney are the
rgans more frequently affected, the screening of HCM and
ialysis patients through the assessment of alpha-
alactosidase A activity in peripheral blood has been pro-
osed to identify undiagnosed Fabry patients. Nevertheless,
his approach, possibly useful in the identification of affected
en despite a significant number of false positives (18),
rovides unreliable results in the screening of female carriers
8). In addition, the screening of large populations may be
xpensive and therefore available only in referral centers. On
he contrary, the non-invasive hallmark we recognized,
haracterized by high specificity and sensitivity, appears easy
o detect in any echocardiography lab and may therefore be
onsidered as a first filter to focus the enzymatic and genetic
ests in a more selected population.
onclusions. Binary appearance of LV endocardial border,
eflecting the endocardial and subendocardial compartmen-
alization of glycosphingolipid material, can be recognized
t two-dimensional echocardiography in patients with FC.
hese findings provide a specific and sensitive non-invasive
ool to distinguish FC from other forms of LV hypertrophy
romptly allowing its specific treatment.
eprint requests and correspondence: Dr. Andrea Frustaci, The
eart and Great Vessels Department “Attilio Reale,” La Sapienza
niversity, viale del Policlinico 155, 00100 Rome, Italy. E-mail:
iocard@rm.unicatt.it.
EFERENCES
1. Desnick RJ, Ioannou YA, Eng CM. -Galactosidase A deficiency:
Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The
Metabolic and Molecular Bases of Inherited Disease. New York, NY:
McGraw-Hill, 2001:3733–74.
2. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry’s
disease in men with left ventricular hypertrophy. N Engl J Med3. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-
Fabry disease in male patients with late onset hypertrophic cardiomy-
opathy. Circulation 2002;105:1407–11.
4. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry
disease in female patients with late-onset hypertrophic cardiomyopa-
thy. Circulation 2004;110:1047–53.
5. Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease:
clinical manifestations of disease in female heterozygotes. J Inherit
Metab Dis 2001;24:715–24.
6. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of
recombinant human alpha-galactosidase A replacement therapy in
Fabry’s disease. N Engl J Med 2001;345:9–16.
7. Frustaci A, Chimenti C, Ricci R et al. Improvement in cardiac
function in the cardiac variant of Fabry’s disease with galactose-
infusion therapy. N Engl J Med 2001;345:25–32.
8. Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Screening for Fabry
disease using whole blood spots fails to identify one-third of female
carriers. Clin Chim Acta 2005;353:201–3.
9. Pieroni M, Chimenti C, Ricci R, et al. Early detection of Fabry
cardiomyopathy by tissue Doppler imaging. Circulation 2003;107:
1978–84.
0. Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced
cardiovascular magnetic resonance in Anderson-Fabry disease. Evi-
dence for a disease specific abnormality of the myocardial interstitium.
Eur Heart J 2003;24:2151–5.
1. Nagueh SF, Bachinski LL, Meyer D, et al. Tissue Doppler imaging
consistently detects myocardial abnormalities in patients with hyper-
trophic cardiomyopathy and provides a novel means for an early
diagnosis before and independently of hypertrophy. Circulation 2001;
104:128–30.
2. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC,
Pennell DJ. Toward clinical risk assessment in hypertrophic cardio-
myopathy with gadolinium cardiovascular magnetic resonance. J Am
Coll Cardiol 2003;41:1561–7.
3. Schiller NB, Shah PM, Crawford M, et al. Recommendations for
quantitation of the left ventricle by two-dimensional echocardiogra-
phy: American Society of Echocardiography Committee on Standards,
Subcommittee on Quantitation of Two-Dimensional Echocardio-
grams. J Am Soc Echocardiogr 1989;2:358–67.
4. Allen MN. Echocardiography. 2nd edition. Philadelphia, PA: Lippin-
cott Williams & Wilkins, 1999.
5. Feigenbaum H, Armstrong WF, Ryan T. Echocardiography. 6th
edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2004.
6. Glass RB, Astrin KH, Norton KI, et al. Fabry disease: renal sono-
graphic and magnetic resonance imaging findings in affected males and
carrier females with the classic and cardiac variant phenotypes.
J Comput Assist Tomogr 2004;28:158–68.
7. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic
resonance in cardiac amyloidosis. Circulation 2005;111:186–93.
8. Kotanko P, Kramar R, Devrnja D, et al. Results of a nationwide
screening for Anderson-Fabry disease among dialysis patients. J Am1995;333:288–93. Soc Nephrol 2004;15:1323–9.
